Skip to main content

Table 7 TGLS in healthy controls and patients with or without drug adjustment

From: Layer‐specific strain echocardiography may reflect regional myocardial impairment in patients with hypertrophic cardiomyopathy

  Healthy controls (n = 30) Patients without drug adjustment (n = 22) Patients received drug adjustment (n = 28)
  Baseline echo Follow-up echo Baseline echo Follow-up echo Baseline echo Follow-up echo
LVEF, % 64.3 ± 6.4 65.6 ± 5.7 70.8 ± 6.1 69.6 ± 7.3 72.7 ± 5.4 73.7 ± 6.5
Resting LVOT gradient, mmHg 7.8 ± 1.6 7.0 ± 2.1 18.2 (6.1—30.3) 18.0 (6.0—30.0) 70.0 (47.0—90.0) 40.0 (17.0—68.0) *
Global LS, % -20.3 ± 6.84 -22.6 ± 5.49 -12.3 ± 7.87 -12.3 ± 8.79 -13.7 ± 10.10 -14.7 ± 9.70
TGLS basal, % −2.17 ± 1.66 −2.58 ± 1.03 -1.22 ± 2.10 -1.19 ± 2.70 -1.01 ± 2.14 -1.71 ± 2.98**
TGLS mid, % −3.58 ± 2.29 −3.27 ± 2.88 -3.28 ± 2.48 -2.98 ± 2.39 -2.72 ± 2.50 -3.31 ± 2.64**
TGLS apex, % −10.54 ± 3.20 −11.10 ± 4.21 -9.9 ± 3.99 -9.5 ± 3.75 -9.8 ± 4.11 -10.21 ± 3.79
Number of segments with abnormal TGLS 6 8 72 79 145 84***
  1. LVEF left ventricular ejection fraction; LVOT left ventricular outflow tract; LS longitudinal strain; TGLS transmural gradient of longitudinal strain. *, **, ***: p < 0.05, 0.01, 0.001, compared with baseline data in patients received drug adjustment